{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:15Z","timestamp":1792979895694,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijid.2025.107961","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T13:56:23Z","timestamp":1750254983000},"page":"107961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Switching to bictegravir\/emtricitabine\/tenofovir alafenamide from efavirenz\/emtricitabine\/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)"],"prefix":"10.1016","volume":"158","author":[{"given":"Roberta","family":"Gagliardini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6624-7917","authenticated-orcid":false,"given":"Marta","family":"Camici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Bellagamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Ottou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Plazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vergori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Mondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Fusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Paulicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Tempestilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pinnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Grilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Mastrorosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"De Zottis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Del","family":"Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.107961_bib0001","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","article-title":"A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population","volume":"7","author":"Chawla","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2025.107961_bib0002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/s12879-025-10858-x","article-title":"INSTIs-centered antiviral regimens for first-line treatment of HIV\/AIDS: a network meta-analysis and cost-effectiveness analysis","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2025.107961_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.13446","article-title":"BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022","volume":"23","author":"Waters","year":"2022","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2025.107961_bib0004","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2147\/TCRM.S2205","article-title":"Atriplatrade mark - HIV therapy in one pill","volume":"4","author":"Julg","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ijid.2025.107961_bib0005","series-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Department of Health and Human Services","article-title":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2024"},{"key":"10.1016\/j.ijid.2025.107961_bib0006","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society\u2013USA Panel","volume":"333","author":"Gandhi","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2025.107961_bib0007","series-title":"EACS Guidelines version 12.1, November 2024","year":"2024"},{"key":"10.1016\/j.ijid.2025.107961_bib0008","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4102\/sajhivmed.v18i1.741","article-title":"Efavirenz and neuropsychiatric effects","volume":"18","author":"Dheda","year":"2017","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.ijid.2025.107961_bib0009","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","article-title":"Estimated glomerular filtration rate, chronic kidney disease, and antiretroviral drug use in HIV-positive patients","volume":"24","author":"Mocroft","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.107961_bib0010","first-page":"109","article-title":"The role of HIV and antiretroviral therapy in bone disease","volume":"13","author":"Gutierrez","year":"2011","journal-title":"AIDS Rev"},{"key":"10.1016\/j.ijid.2025.107961_bib0011","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0000000000002067","article-title":"Randomized clinical trial on efficacy of fixed-dose efavirenz\/tenofovir\/emtricitabine on alternate days versus continuous treatment","volume":"33","author":"Bellagamba","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.107961_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052562","article-title":"Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.107961_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107049","article-title":"Rapid ART initiation with bictegravir\/emtricitabine\/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study)","volume":"63","author":"Camici","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2025.107961_bib0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/ciae012","volume":"79","author":"Wang","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.107961_bib0015","doi-asserted-by":"crossref","first-page":"ofae446","DOI":"10.1093\/ofid\/ofae446","article-title":"Comparative effectiveness of switching to bictegravir from dolutegravir-, efavirenz-, or raltegravir-based antiretroviral therapy among individuals with HIV who are virologically suppressed","volume":"11","author":"N\u00fa\u00f1ez","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.107961_bib0016","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/QAD.0000000000004043","article-title":"Impact of switching from EFVIC\/FTC\/TDF to BIC\/FTC\/TAF on psychiatric symptoms and neurocognition","volume":"39","author":"Vergori","year":"2025","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.107961_bib0017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijid.2025.107961_bib0018","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2025.107961_bib0019","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/QAD.0000000000003865","article-title":"Switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir-based therapy","volume":"38","author":"Orkin","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.107961_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1874613601509010023","article-title":"Epidemiology and management of antiretroviral-associated cardiovascular disease","volume":"9","author":"Chastain","year":"2015","journal-title":"Open AIDS J"},{"key":"10.1016\/j.ijid.2025.107961_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw061","article-title":"Risk of cardiovascular events among patients initiating efavirenz-containing versus efavirenz-free antiretroviral regimens","volume":"3","author":"Rosenblatt","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.107961_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.33393\/dti.2023.2529","article-title":"Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir","volume":"17","author":"Khemla","year":"2023","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.ijid.2025.107961_bib0023","doi-asserted-by":"crossref","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab621","article-title":"Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides","volume":"9","author":"Mallon","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.107961_bib0024","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/COH.0000000000000833","article-title":"Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV","volume":"19","author":"Capeau","year":"2024","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijid.2025.107961_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. cohort study 2021","volume":"24","author":"Mallon","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijid.2025.107961_bib0026","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/jac\/dkr360","article-title":"Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals","volume":"66","author":"Poeta","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2025.107961_bib0027","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.107961_bib0028","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s40506-019-00203-7","article-title":"Update on adverse effects of HIV integrase inhibitors","volume":"11","author":"Kolakowska","year":"2019","journal-title":"Curr Treat Options Infect Dis"},{"key":"10.1016\/j.ijid.2025.107961_bib0029","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/FPC.0b013e328302cd41","article-title":"OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine","volume":"18","author":"Wang","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.ijid.2025.107961_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225001857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225001857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:14:23Z","timestamp":1762366463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225001857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"alternative-id":["S1201971225001857"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.107961","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide from efavirenz\/emtricitabine\/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.107961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107961"}}